Vivos Therapeutics, Inc. (Nasdaq: VVOS) announced it entered into twelve exchange agreements with Streeterville Capital, LLC on August 31, 2026, converting $2,861,270 of outstanding principal from a secured promissory note into 11,445,080 shares of common stock at $0.25 per share.

The company also previously exchanged $3,250,000 of principal under the same note for 2,500 shares of Series B Non-Convertible Preferred Stock and 1,812,031 shares of common stock, as announced on August 4, 2026.

Following both transactions, the outstanding balance of the Streeterville note, inclusive of fees and original issue discount, stands at approximately $3.7 million as of August 31, 2026, down from the original principal amount of $8,225,000 on June 9, 2025.

The company said the exchanges are expected to reduce liabilities and increase stockholders' equity, as the partitioned notes are surrendered and cancelled. The final amounts will be reflected in financial statements for the quarter in which each exchange settles.

Vivos noted the transactions are part of its efforts to satisfy Nasdaq continued listing requirements related to stockholders' equity. The company cautioned that the issuance of common stock in the exchanges will dilute existing stockholders, and that future exchanges or financings may result in additional dilution.